Divi’s Laboratories: March ’22 Results Update
Moneylife Digital Team 01 June 2022
In the March quarter, Divi’s Laboratories (Divi’s) clocked stellar revenue growth of 41% y-o-y (year-on-year) to Rs2,518 crore, led by strong performance in the custom synthesis segment which performed well on back of molnupiravir (COVID drug) opportunity. Custom synthesis contributed 66% of total revenue in Q4FY21-22. Generic business faced headwinds because of intense pricing pressure in the...
Archived Premium Content
This article is outside your subscription period. You can buy this article individually.
SINGLE ARTICLE
Rs 50-Rs 100 + GST
Access will be given ONLY to this article.
 
Already a subscriber ? Log in
Free Helpline
Legal Credit
Feedback